{"id":"W4389241247","doi":"10.1007/s00277-023-05552-4","title":"A multicenter phase Ib trial of the histone deacetylase inhibitor entinostat in combination with pembrolizumab in patients with myelodysplastic syndromes/neoplasms or acute myeloid leukemia refractory to hypomethylating agents","year":2023,"lang":"en","type":"article","venue":"Annals of Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"National Cancer Institute; National Institutes of Health; Astellas Pharma; Sierra Oncology; Taiho Pharmaceutical; Incyte; CTI Biopharma; MorphoSys; Celgene; Astex Pharmaceuticals; Servier; Pfizer; Constellation Pharmaceuticals; Agios Pharmaceuticals; Bristol-Myers Squibb","keywords":"Medicine; Internal medicine; Myelodysplastic syndromes; Hypomethylating agent; Oncology; Pembrolizumab; Myeloid leukemia; Lenalidomide; Decitabine; Cancer; Bone marrow; Multiple myeloma; Immunotherapy; DNA methylation","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005043593,0.0003006239,0.001000349,0.00110139,0.00005649573,0.000008594439,0.0002823566,0.0001960502,0.00004857983],"category_scores_gemma":[0.001286672,0.0001921181,0.0000911368,0.001803891,0.0002485457,0.0001652732,0.000221554,0.0005320334,0.00002186417],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003312948,"about_ca_system_score_gemma":0.0007764136,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001539305,"about_ca_topic_score_gemma":0.0001699632,"domain_scores_codex":[0.9967274,0.0003081831,0.0009610368,0.0004909592,0.0008290941,0.0006833],"domain_scores_gemma":[0.9977679,0.0006913925,0.0004779558,0.0005350294,0.0003446452,0.0001831369],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8301929,0.00836328,0.1291556,0.001751422,0.0008852804,0.002149968,0.00523368,0.0002716029,0.01263558,0.0001138519,0.002982587,0.006264297],"study_design_scores_gemma":[0.5722783,0.03626826,0.2977302,0.003111673,0.0002797819,0.0002563097,0.000974523,0.002116847,0.08601564,0.00003810777,0.0002521551,0.000678155],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9963257,0.00002116386,0.00001772489,0.0008417339,0.0001746382,0.002465534,0.00004967316,0.00003260189,0.0000712606],"genre_scores_gemma":[0.9989261,0.00003409846,0.0002988079,0.0002033639,0.00001602115,0.0001513514,0.00009257092,0.0000562702,0.0002214408],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2579145,"threshold_uncertainty_score":0.783435,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04112445603740638,"score_gpt":0.3582295439260402,"score_spread":0.3171050878886338,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}